June 24, 2008 - Sciele Pharma, Inc. (NASDAQ:SCRX) and Novo Nordisk Inc. announced that the U.S. Food and Drug Administration (FDA) approved PrandiMet(TM) (repaglinide and metformin HCl) tablets, the first and only fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin(R)) and insulin sensitizer, metformin, for the treatment of type 2 diabetes.
Under a previously announced agreement, Sciele Pharma will exclusively market PrandiMet(TM) to physicians in the U.S. Sciele Pharma anticipates that PrandiMet(TM) will be available to physicians and patients in the U.S. in the second half of 2008. PrandiMet(TM) has been approved to lower the blood glucose in adult patients with type 2 diabetes whose hyperglycemia cannot be controlled satisfactorily by meglitinide and/or metformin... Sciele Pharma's Press Release - Novo Nordisk's Press Release -
